Precigen (PGEN)

• Market cap: $1.59B
• 1 day: -1.77%
• 5 days: 23.96%
• 1 month: 9.07%
• 3 months: 35.67%
• 6 months: 20.6%
• Year to date: 3.97%
• 1 year: 192.76%
• 5 years: -36.88%
• 10 years: -82.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Employees: 47